Kornimate/medical-research-clean huggingface dataset:
hfr a-equilibrium on cardiovascular stability

Conditions: Hypotension

Summary: aim of the present randomized controlled multinational trial is the comparison of a novel biofeedback system on sodium profiling applied to a endogenous hemodiafiltration therapy, with the standard (no sodium profiling) hemodiafiltration technique on the intradialytic overall and cardiovascular stability.

online hemodiafiltration (ol-hdf) has been recently associated with better patient survival in comparison with standard hemodialysis in some large observational studies (canaud et al, ki, 2006; vilar et al, cjasn , 2009) supporting the hypothesis that convection can improve patients outcomes. moreover, it has been demonstrated in randomized controlled trials (locatelli et al, journal american society of nephrology, 2010) that ol-hdf significantly reduced the frequency of intradialytic hypotension. nonetheless, the associated comorbidities and ageing of dialysis population require further devices able to improve treatment tolerance. among these tools, the sodium profiling and biofeedback system seem to be promising to accomplish this task. but the correct intradialytic sodium balance is still far away today to be easily achieved. the use of an automated adaptive system dialysis to the sodium profiling has been investigated in a feasibility trial (colì et al international journal artificial organs, 2003). they also investigated the impact of such a device on treatment tolerance. the aim of this randomized multinational multicenter controlled trial is to evaluate the impact of sodium profiling applied to a endogenous hemodiafiltration technique on the intradialytic cardiovascular stability in comparison to standard no profiled endogenous hemodiafiltration.

Eligibility criteria:
inclusion criteria: * patients with more than 30% of dialysis complicated by hypotension * age between 18 and 85 yers * time on dialysis greater than 6 months * residual creatinine clearance less than 2 ml/min/1.73 m2 * native fistula or central venous catheter with blood flow rate greater than 250 ml/min exclusion criteria: * life expectancy less than 1 year * solid active neoplasm * pregnancy * major event in the previous 3 months (ictus, myocardial infarction, cachexia)
topical anesthetic use in pessary management

Conditions: Pain

Summary: the purpose of this study is to evaluate if lidocaine-prilocaine (emla 5%) cream can reduce pain and discomfort at the time of vaginal pessary removal and insertion. half of the participants will receive lidocaine-prilocaine (emla 5%) cream and the other half will receive a placebo cream.

lidocaine-prilocaine (emla 5%) cream has been shown to be effective in reducing pain during minor gynecologic procedures. the primary objective of this trial is to determine if the use of 5% emla cream at the time of pessary removal and insertion reduces pain when compared to the use of placebo cream. participants will be randomized to receive either 10 grams of 5% emla cream (4 ml) or 4 ml of placebo cream (aqueous cream bp). cream will be applied in office at the time of pessary removal and insertion.

Eligibility criteria:
inclusion criteria: * women in the loyola urogynecology clinic who use a pessary for management of pelvic organ prolapse (pop) or urinary incontinence (ui) * read and speak the english language exclusion criteria: * non-english speaking * allergy or contraindication to topical anesthetic * participation/randomization in the study at a previous visit * currently pregnant or lactating or planning a pregnancy within the next 6 months

Keywords: pessary pain emla lidocaine prilocaine
dental and oral finding in israeli children with past intrauterine growth retardation (iugr)

Conditions: Dental Caries

Summary: oral status and early childhood caries (ecc) in israeli children with past iugr


Eligibility criteria:
inclusion criteria: * children who were born and diagnosed with iugr exclusion criteria: * children whos mothers have been diagnosed with diabetes or high blood pressure children with genetic disorders multiple babies pregnancy

Keywords: past iugr ecc oral findings in children with past iugr
lorazepam-induced toxicity in the aged

Conditions: Anxiety Disorders; Generalized Anxiety Disorder

Summary: this study will compare the effects of an acute dose of lorazepam to a placebo in elderly patients with generalized anxiety disorder (gad).

gad is among the most common anxiety disorders in the elderly population. the drug lorazepam is widely utilized in the treatment of elderly individuals with gad. however, single doses of lorazepam have been associated with cognitive toxicity that is typically evident between 1 and 2.5 hours after the drug is administered. the toxic effects include decreased memory and increased swaying, which has been associated with greater risk for falls. patients have 4 study visits. a psychiatric evaluation and a memory test are given at the first visit. during the second study visit, patients have a physical exam, an electrocardiogram (ecg), a neuropsychological assessment, an optional magnetic resonance imaging (mri) brain scan, and other laboratory tests. on the third and fourth visits, patients are randomized to receive either their highest daily dose of lorazepam or placebo. performance effects and postural sway are determined before drug administration and at 1, 2.5, and 5 hours after the drug is given. blood samples for the determination of drug levels are also obtained.

Eligibility criteria:
inclusion criteria: * lorazepam treatment for at least 3 months * cognitively intact note: individuals who are unable or unwilling to have an mri may be included exclusion criteria: * major psychiatric disorder other than gad * significant medical illness which may increase the likelihood of adverse reactions to lorazepam * severe loss of hearing or vision * current or past history of alcohol dependence * substance abuse within the past 6 months * mri evidence of infection, infarction, or other lesions suggestive of intervening neurological disease * clinical symptoms that suggest neurological disease * dementia or other mental syndromes or disorders

Keywords: anxiety
influence of an inspiratory muscle fatigue protocol on older adults on respiratory muscle strength and heart rate variability

Conditions: Healthy

Summary: respiratory muscle training represents an effective method increasingly utilized in both sports and healthcare domains, employing various devices, among which threshold devices are prominent. the aim of this study is to determine the relationship between inspiratory muscle fatigue and maximal inspiratory pressure, diaphragmatic strength (guided by ultrasound image) and heart rate variability. according to our hypothesis, the execution of a protocol inducing inspiratory muscle fatigue in older adults could influence cardiorespiratory function. in this study, subjects will be divided into three groups: the experimental group , the activation group and the control group. measurements of variables, such as maximal inspiratory pressure, heart rate variability and diaphragmatic strength (ultrasound image), will be conducted.

this is a randomized control trial. the experimental group (eg) will perform the diaphragmatic fatigue protocol using a specific inspiratory endurance test, in which volunteers, one-on-one, and in a single session, will breathe against submaximal inspiratory loads equivalent to 60% of their maximum inspiratory pressure (mip) through a threshold valve device. the participants will follow a free pattern of breathing until they are unable to establish flow during at least 3 maximum inspiratory efforts. the activation group (ag) will perform the protocol of 2 sets of 30 repetitions at 15% of their mip, one-on-one, and in a single session, using a threshold valve device. the control group will do a seat and wait. the interventions will be supervised by a physiotherapist. the primary outcomes will be respiratory muscle strength will be assessed using a respiratory pressure meter or manometer designed, and with ultrasound image measuring the cross sectional area of the diaphragm at 8-9th rib level and speed of contraction with a deep and fast inspiratory manoeuver. this will be done immediately before intervention and immediately after intervention heart rate variability (hrv) will be assessed using a heart rate sensor polar h10.

Eligibility criteria:
inclusion criteria: * being over 60 years old. * physical independence in terms of gait and transfers. exclusion criteria: * having any pathology that prevents the performance of physical activity. * subjects with impaired cognitive abilities. * subjects with tympanic perforation or middle-inner ear pathology. * subjects with pulmonary hypertension, decompensated heart or respiratory failure. * subjects who have undergone lower limb surgery within the past 12 months.
vaginal dhea for women after breast cancer

Conditions: Vaginal Dryness; Breast Cancer; Urinary Incontinence; Quality of Life; Sexual Satisfaction

Summary: there does not appear to be a consensus regarding the treatment of vaginal dryness in women who have a contraindication to the use of estrogen products. dhea, when used locally, may improve the symptoms of vaginal dryness due to its chemical properties.


Eligibility criteria:
inclusion criteria: * women post menopausal aged 35-55, suffering from vaginal dryness, secondary to chemotherapy for breast cancer, within 5 years of diagnosis. follicle stimulating hormone and estradiol levels in the post menopausal range are needed. exclusion criteria: * women using products to alleviate vaginal dryness. * women taking medication for urinary incontinence * women not sexually active, for other reasons.

Keywords: vaginal dryness breast cancer urinary incontinence quality of life sexual satisfaction
effect of preoperative sleep intervention on postoperative delirium in adult patients undergoing cardiac surgery

Conditions: Delirium - Postoperative; Sleep Problems; CABG; Valve Surgery

Summary: this is a multicenter, randomized, controlled clinical trial aimed to determine whether preoperative sleep interventions could reduce the incidence of adverse outcomes, such as postoperative delirium, in adult patients undergoing cardiac surgery. the study will include adult patients undergoing coronary artery bypass grafting and/or valve surgery with concomitant sleep disorders, as assessed by the pittsburgh sleep quality index. all participants will be randomly assigned to placebo, placebo + cognitive behavioral therapy, and melatonin + cognitive behavioral therapy in a 1:1:1 ratio. the primary outcome is the incidence of postoperative delirium within 7 days after surgery or before discharge, and secondary outcomes include postoperative cognitive function, sleep quality, and severity and duration of delirium. the results of this study will provide suggestions for the prevention of delirium after cardiac surgery.


Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years. 2. scheduled for elective coronary artery bypass grafting and/or valve surgery. 3. preoperative pittsburgh sleep quality index (psqi) score ≥ 5. exclusion criteria: 1. history of neurosurgery, cerebral hemorrhage, cerebral infarction, delirium, dementia, or other neurological diseases. 2. history of mental illness. 3. habitual heavy drinking. 4. american society of anesthesiologists (asa) grade iv or above. 5. severe hepatic dysfunction (child-pugh grade c) or renal dysfunction (chronic kidney disease stages 3-4). 6. contraindications to melatonin use, such as allergies to melatonin-related ingredients. 7. currently taking melatonin, melatonin receptor agonists, sleep-related medications, sedatives, antipsychotic medications, or opioids. 8. inability to communicate due to hearing or speech impairment, or refusal to provide informed consent.
assessment of physical exercise using stationary bicycle for pregnant women with risk for preeclampsia development

Conditions: Pre-eclampsia; Hypertension, Pregnancy-Induced; Pregnancy, High-Risk

Summary: introduction: hypertensive disorders during pregnancy are an important issue in global public health. it is current the leading cause of maternal mortality in brazil. objective: to assess the effect of physical exercise using stationary bicycle through blood pressure and heart rate measurements, incidence of pre-eclampsia and quality of life survey in pregnant women with chronic high blood pressure, previous preeclampsia pregnancies or both factors associated comparing to a group with no intervention. verify the type of births, maternal and perinatal outcomes in both groups. methodology: this randomized clinical trial enrolled pregnant women presenting chronic hih blood pressure, previous pre-eclampsia experience or both. women from 12 to 20 gestational weeks were selected from the prenatal outpatient clinic and randomly allocated to the study or non-interventional group. women at the study group performed physical exercise using stationary bicycle (horizontal bench model) during 20 minutes, once a week. the heart rate was maintained at 20% above resting heart rate and up to 140 bpm. blood pressure and heart rate measurements were evaluated before and after exercise. the non-intervention group followed regular prenatal routine with weekly returns for heart rate and blood pressure measurements. both groups fulfilled the quality of life survey (sf-36 questionnaire) at three times: between 12 and 20 weeks; 28 and 32 weeks and 36 and 41 weeks of gestation. after that data of parturition will be analyzed to compare the incidence of pre-eclampsia, types of birth, maternal and perinatal outcomes.

significance was assumed as p\<.5%.

Eligibility criteria:
inclusion criteria: * pregnant with 12 to 20 weeks gestational * have chronic blood pressure, previous pre-eclampsia or both * able to perform a exercise exclusion criteria: * multiple pregnancy * systemic lupus erythematosus * heart disease * neurological disease * renal failure * persistent vaginal bleeding * isthmic-cervical insufficiency

Keywords: pregnant women pre-eclampsia exercise hypertension, pregnancy-induced parturition
compound xiwujia granules treat chronic fatigue syndrome

Conditions: Chronic Fatigue Syndrome

Summary: to observe the improvement of chalder scale score in patients with chronic fatigue syndrome treated by compound ciwujia granules. improvement =\[(baseline score - post-treatment score)/baseline score\]\*100%

after being informed of the study and potential risks, all subjects who have given informed consent undergo a 2-week screening period to determine eligibility, and on day 0, subjects who meet eligibility requirements will be randomly assigned in a double-blind way. the patients were treated with compound xiwujia granules + guipi granules/placebo (experimental group) and compound xiwujia granules/placebo + guipi granules (positive control group) at a ratio of 1:1 for 6 weeks. compound ciwujia granules/placebo 8g per bag, 2 times a day, 1 bag each time, guipi granules, 3g per bag, taken with boiling water. 1 bag (3g) at a time, 3 times a day.

Eligibility criteria:
inclusion criteria: * meet the diagnostic criteria of western medicine for chronic fatigue syndrome; * meet the diagnostic criteria of spleen and kidney deficiency syndrome or heart and spleen deficiency syndrome of traditional chinese medicine; * chalder scale score greater than 12 points; * age 18-70 years old, gender is not limited; * agree to participate in this clinical study, voluntarily sign informed consent, and agree to participate in visits, examinations, and treatments according to the requirements of the research protocol. exclusion criteria: * combined with mental disorders such as severe anxiety and severe depression; * secondary fatigue caused by drugs or other reasons; * patients with serious primary diseases such as cardiovascular and cerebrovascular, liver, kidney and hematopoietic system, malignant tumors, and other serious complications; abnormal liver and kidney function alt, ast≥ 1.5 times the upper limit of normal value, cr \> the upper limit of normal value; * women who are pregnant, breastfeeding or who may become pregnant in the study and cannot use effective contraception; * have received relevant treatment and may affect the observed effect indicators; * suspected to have a history of drug abuse or other patients who do not meet the eligibility criteria; * allergic physique and allergic to the drug; * uncontrolled hypertension (dbp \> 100mmhg or sbp \> 160 mmhg); * diabetic patients; * those that the researcher thinks are not suitable for participating in this study.
search for serum/plasma biomarkers in pompe's disease

Conditions: Late Onset Pompe Disease; Pompe Disease

Summary: this study aims to analyze serum and plasma samples from patients with late onset pompe disease treated and not treated with enzyme replacement therapy (ert) to identify microrna that could be specific of the disease. the investigators will correlate the concentration of these microrna with several muscle function tests and quantitative muscle mri to know whether they are good biomarkers of progression.


Eligibility criteria:
inclusion criteria: * genetic confirmation of pompe disease exclusion criteria: * pregnancy

Keywords: pompe microrna biomarker muscle mri glycogenosis
a study of paclitaxel and carboplatin in combination with bexarotene oral capsules in patients with advanced lung cancer

Conditions: Carcinoma, Non-small-cell Lung

Summary: the primary aim is to evaluate the safety (phase i components) of administering bexarotene (targretin®, lgd1069) oral capsules in combination with two taxol® and carboplatin (paraplatin®) schedules to patients with stage iiib and iv non-small cell lung cancer. this study will also evaluate the preliminary efficacy (phase ii component) of bexarotene oral capsules in combination with the weekly taxol® schedule and carboplatin in these patients.

the phase i portion of the study will evaluate the safety of administering bexarotene oral capsules daily at two dose levels (300 mg/m2 and 400 mg/m2) in combination with carboplatin and taxol®. at least 6 patients will be entered onto each dose level. doses will not be escalated over the course of treatment of an individual patient. the recommended phase ii dose is defined as the highest dose of bexarotene oral capsules (300 mg/m2 or 400 mg/m2) in combination with carboplatin and taxol® that induces dlt in fewer than or equal to 33% of patients. the sequential phase ii portion of the study will evaluate the efficacy of bexarotene oral capsules in combination with carboplatin and weekly taxol® in patients with advanced non-small cell lung cancer. the efficacy will be gauged according to the rate of major response where, by definition, a major response occurs if a patient achieves either complete remission (cr) or partial remission (pr). for these patients a true response rate of 20% or greater is sufficiently large to warrant further investigation. a true response rate of 10% or less indicates that the combination is less active.

Eligibility criteria:
inclusion criteria: * unresectable stage iiib or iv nsclc * adequate bone marrow, hepatic, thyroid and renal function exclusion criteria: * peripheral neuropathy \>= grade 2 * gastrointestinal abnormalities * known hypersensitivity to retinoids

Keywords: nsclc bexarotene targretin
deep brain stimulation lead localization after implantation

Conditions: Parkinson Disease

Summary: deep brain stimulation (dbs) is an effective treatment for a variety of neurological and psychiatric disorders, with more than 200,000 patients implanted with dbs devices worldwide. parkinson's disease is one of the typical indications.the clinical outcomes of dbs depends on the accurate implantation of the lead, and the identification of the lead locations is the basis for evaluating the effectiveness of the treatment. the aim of this study is to localize the implantation position of the lead based on postoperative mri images and to reconstruct the relative spatial relationship between the lead and the stimulation target. by comparing with the lead position identified based on postoperative ct, this study will evaluate the accuracy of identifying the dbs lead position directly from mri. this study may help to optimise the stimulation parameters and investigate the best stimulation targets for dbs patients.


Eligibility criteria:
inclusion criteria: * parkinson's disease patients with dbs devices, dbs implanted for at least 1 month. * ability to tolerate dbs turn-off for at least 30 minutes. * dbs devices do not contain the ferromagnetic material. * the patients can fully understand the content of the trial and sign the informed consent form. * able to comply to the requirements of this study. exclusion criteria: * presence of other concomitant diseases that have or require implantation of pacemakers, defibrillators, cochlear implants, or other neurostimulation devices. * patients who are abnormally sensitive to temperature or allergic to heat. * patients with severe psychiatric disorders or cognitive impairment.

Keywords: deep brain stimulation lead localization mri
efficacy and safety of low-dose ticagrelor

Conditions: Coronary Artery Disease

Summary: guideline recommendations on the use of dual antiplatelet therapy have been formulated that ticagrelor 90 mg twice daily plus aspirin in preference to clopidogrel 75mg daily plus aspirin for acs patients. recent study found that ticagrelor 90mg twice a day orally could significantly reduce the occurrence of clopidogrel resistance and adverse cardiovascular events. the previous studies have reported that half-dose ticagrelor had the similar inhibitory effect on platelet aggregation as the standard-dose ticagrelor, which was significantly stronger than that in the clopidogrel group. one-quarter standard-dose ticagrelor provided greater degree of platelet inhibition than standard dose clopidogrel in chinese patients with stable cad. but large-scale clinical trials are still needed to confirm the effects of low-dose ticagrelor on platelet function in chinese patients with coronary heart disease.

dual antiplatelet therapy (dapt) with aspirin and p2y12 receptor inhibitor remains a cornerstone in the secondary prevention of coronary artery disease (cad). clopidogrel is one of the most commonly used antithrombotic agent that inhibits the platelet p2y(12) adenosine diphosphate (adp) receptor. ticagrelor is an oral, reversibly-binding, direct-acting p2y12 receptor antagonist used clinically for the prevention of atherothrombotic events in patients with acute coronary syndromes (acs). guideline recommendations on the use of dual antiplatelet therapy have been formulated that ticagrelor 90 mg twice daily plus aspirin in preference to clopidogrel 75mg daily plus aspirin for acs patients. recent study found that ticagrelor 90mg twice a day orally could significantly reduce the occurrence of clopidogrel resistance and adverse cardiovascular events. the previous studies have reported that half-dose ticagrelor had the similar inhibitory effect on platelet aggregation as the standard-dose ticagrelor, which was significantly stronger than that in the clopidogrel group. one-quarter standard-dose ticagrelor provided greater degree of platelet inhibition than standard dose clopidogrel in chinese patients with stable cad. but large-scale clinical trials are still needed to confirm the effects of low-dose ticagrelor on platelet function in chinese patients with coronary heart disease.

Eligibility criteria:
inclusion criteria: * patients with coronary artery disease exclusion criteria: * younger than 18 years of age; * anti-platelet therapy with clopidogrel or ticagrelor for less than 5 days; * previous or current treatment with any other potentially confounding drugs.